Yalcin, KDegertekin, HBozdayi, M2024-04-242024-04-2420040038-43481541-8243https://doi.org/10.1097/01.SMJ.0000091068.87861.BAhttps://hdl.handle.net/11468/17260We report the first case of a woman having chronic hepatitis B treated with a combination therapy of recombinant hepatitis B vaccine and lamivudine for 18 months. The main aims of such a combined therapy were to assess whether the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the emergence of a mutant HBV and lead to sustained hepatitis B e antigen seroconversion with undetectable serum HBV DNA. The data from the present case demonstrated that combination of anti-HBV vaccine and lamivudine did not eliminate viral DNA despite prolonged treatment and did not have any effect on preventing resistant-type HBV. Although the combined therapy failed to reach the therapeutic endpoints, it concerned a single and unique patient. Hepatitis B vaccine and lamivudine for HBV treatment should be further investigated in randomized controlled trials.eninfo:eu-repo/semantics/closedAccessHepatitis BLamivudineRecombinant VaccineArticle974407409WOS:0002221722000212-s2.0-18427306281510883910.1097/01.SMJ.0000091068.87861.BAQ2Q3